Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017:2017:9401606.
doi: 10.1155/2017/9401606. Epub 2017 Nov 20.

Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes

Jia Liu  1 , Yanjin Hu  1 , Yuan Xu  1 , Yumei Jia  1 , Li Miao  1 , Guang Wang  1
Affiliations

Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes

Jia Liu et al. Int J Endocrinol. 2017.

Abstract

Aims: The present study assessed the therapeutic effect of exenatide and metformin as the initial therapy on overweight/obese patients with newly diagnosed type 2 diabetes (T2D).

Methods: The prospective, nonrandomized, interventional study enrolled a total of 230 overweight or obese patients with newly diagnosed T2D who were administrated exenatide or metformin hydrochloride for 12 weeks.

Results: 224/230 patients, including 106 in the exenatide group and 118 in the metformin group, completed the 12-week treatment. Both exenatide and metformin significantly decreased the HbA1c levels in overweight/obese patients with newly diagnosed T2D (all P < 0.05). The reduction in HbA1c and the proportion of patients with HbA1c < 7.0% (53 mmol/mol) were higher in the exenatide group than in the metformin group (all P < 0.05). The exenatide treatment caused a greater decline in the body weight and BMI as compared to the metformin treatment (all P < 0.01). The exenatide treatment (β = 0.41, P < 0.01) and baseline HbA1c level (β = -0.84, P < 0.01) were independent influencing factors for the decrease in HbA1c level.

Conclusions: For an initial therapy in overweight/obese patients with newly diagnosed T2D, exenatide causes a better glycemic control than metformin. This trial is registered with NCT03297879.

PubMed Disclaimer

References

    1. Guariguata L., Whiting D. R., Hambleton I., Beagley J., Linnenkamp U., Shaw J. E. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Research and Clinical Practice. 2014;103(2):137–149. doi: 10.1016/j.diabres.2013.11.002. - DOI - PubMed
    1. Garber A. J. Obesity and type 2 diabetes: which patients are at risk? Diabetes, Obesity and Metabolism. 2012;14(5):399–408. doi: 10.1111/j.1463-1326.2011.01536.x. - DOI - PubMed
    1. American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. 2013;36(Supplement 1):S11–S66. doi: 10.2337/dc13-S011. - DOI - PMC - PubMed
    1. Derosa G., Franzetti I. G., Querci F., et al. Exenatide plus metformin compared with metformin alone on β-cell function in patients with type 2 diabetes. Diabetic Medicine. 2012;29(12):1515–1523. doi: 10.1111/j.1464-5491.2012.03699.x. - DOI - PubMed
    1. Diamant M., Van Gaal L., Guerci B., et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. The Lancet Diabetes and Endocrinology. 2014;2(6):464–473. doi: 10.1016/S2213-8587(14)70029-4. - DOI - PubMed

Associated data

LinkOut - more resources